LUMICEF® (brodalumab) is a recombinant fully human monoclonal antibody and the only biologic treatment for moderate to severe plaque psoriasis that selectively targets the IL-17 receptor subunit A.  By binding to IL- 17RA, it inhibits the biological activity of IL-17A, IL-17C, IL-17F, IL-17E (IL-25) and heterodimeric IL-17A/F which are actively enrolled in the pathogenesis of plaque psoriasis. By blocking the biological activity of these proinflammatory cytokines, LUMICEF® inhibits inflammation and improves the clinical symptoms significantly associated with psoriasis.